Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of PSA-EPO for anemia in chronic kidney disease
ACTRN12613000504718Phase 2Recruiting
- Sponsor
- Xenetic Biosciences, Inc.
- Start
- May 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of erepoxen in anemia of renal disease, sponsored by Xenetic Biosciences, Inc. Started May 2013; status: recruiting.
02
Drugs
erepoxen
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on ACTRN12613000504718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000504718.